GE Volume Alert - GE 26.41 General Electric Company $GE Hit

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
GE Volume Alert - GE 26.41 General Electric Company $GE Hit a high of 26.50 Currently 11/07/14 Last price 26.41 +0.05 +0.19% With a day low of 26.21 and a current volume of 26,387,500.

GE General Electric Company Recent Headline News

1 Stock to Invest in the Internet of Things
Motley Fool Staff - Motley Fool - Sat Nov 08, 8:05AM CST
There's been plenty of buzz around the Internet of Things, but it's difficult to find clear information about what it really means. Let's clear up that confusion. In the video below, you'll learn three things:  We'll explain in plain English what...
TSLA: 240.20 (-1.02), SWIR: 33.90 (+0.30), AMZN: 299.86 (+3.22), GE: 26.41 (+0.05), EBAY: 53.51 (+0.25), QCOM: 69.26 (-1.32), GM: 31.59 (+0.22), GOOGL: 551.82 (+0.13), INTC: 33.58 (-0.24), GOOG: 541.01 (-1.03), AAPL: 109.01 (+0.31), CSCO: 25.33 (+0.07)

Facebook, Skyworks Among IBD 50's Top 5 Tech Earnings
at Investor's Business Daily - Sat Nov 08, 7:02AM CST
With earnings season starting to wind down, companies that reported excellent quarterly earnings growth, such as Faceboook, are likely candidates for a stock watch list. Today's IBD 50 list features five tech stocks that posted superior earnings...
GPRO: 79.06 (+0.30), GE: 26.41 (+0.05), EBAY: 53.51 (+0.25), SWKS: 59.88 (-2.26), ARRS: 30.84 (+0.35), FB: 75.60 (+0.34), GM: 31.59 (+0.22), TSM: 21.82 (+0.02), GOOGL: 551.82 (+0.13), NXPI: 73.54 (+0.07), INTC: 33.58 (-0.24), COL: 84.80 (+0.82), AAPL: 109.01 (+0.31)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.13 (+0.19), KMI: 38.75 (+0.22), HK: 3.24 (+0.34), KSS: 57.22 (+0.41), GE: 26.41 (+0.05), LMT: 186.15 (-3.73), AVAV: 29.81 (-0.65), WMT: 78.77 (+0.96), SNE: 19.62 (-0.08), M: 59.88 (+0.84), SDRL: 21.77 (+0.06), T: 34.91 (+0.19), W: 26.01 (+0.31), OPK: 8.32 (-0.10), QCOM: 69.26 (-1.32), TWTR: 40.31 (-0.53), EPR: 56.61 (+0.23), AAPL: 109.01 (+0.31), HSIC: 128.84 (-1.47), CSCO: 25.33 (+0.07), WFM: 46.81 (+1.96), CY: 10.08 (-0.02), MU: 33.01 (-0.34), SWKS: 59.88 (-2.26), IRM: 38.05 (+1.58), BAC: 17.36 (unch), MO: 49.87 (+0.31), CSX: 35.45 (+0.32), WWAV: 36.93 (-0.53), GILD: 106.45 (-0.49), TXN: 50.90 (unch), BPL: 79.30 (+1.86), JCP: 7.82 (+0.34), JWN: 73.43 (-0.25), BABA: 114.56 (+2.99)

Most active New York Stock Exchange-traded stocks
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KMI: 38.75 (+0.22), F: 14.17 (-0.02), GE: 26.41 (+0.05), RF: 10.16 (-0.07), ABX.TO: 13.79 (+0.82), K.TO: 2.84 (+0.30), ABX: 12.16 (+0.82), BAC: 17.36 (unch), ANR: 2.91 (+0.39), GNW: 8.41 (-0.25), YRI.TO: 4.47 (+0.44), KGC: 2.50 (+0.29), S: 4.72 (+0.03), TWTR: 40.31 (-0.53), AUY: 3.92 (+0.38)

Final Glance: Tools and Appliances companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top tools and appliances companies were mixed at the close of trading:
WHR: 175.81 (+0.97), GE: 26.41 (+0.05)

Charlene Begley Joins Red Hat's Board of Directors
Business Wire - Fri Nov 07, 3:05PM CST
Red Hat, Inc. (NYSE:RHT), the world's leading provider of open source solutions, today announced that Charlene Begley, a former executive at General Electric Company, has been appointed to the company's Board of Directors.
GE: 26.41 (+0.05), RHT: 61.30 (+0.56), WPPGY: 98.70 (+0.93), NDAQ: 43.88 (-0.02)

Middday Glance: Tools and Appliances companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top tools and appliances companies are mixed at 1 p.m.:
WHR: 175.81 (+0.97), GE: 26.41 (+0.05)

Skyworks Price Targets Up On Q4 Beat, Q1 Guidance
at Investor's Business Daily - Fri Nov 07, 11:40AM CST
Skyworks Solutions (SWKS) on Friday received six price target increases from analysts after the radio-frequency chipmaker's fiscal Q4 earnings report late Thursday easily topped Wall Street views. The Woburn, Mass.-based company's outlook for the...
GE: 26.41 (+0.05), SWKS: 59.88 (-2.26), TQNT: 22.07 (-0.82), GM: 31.59 (+0.22), COL: 84.80 (+0.82), AAPL: 109.01 (+0.31), RFMD: 13.23 (-0.53)

Early Glance: Tools and Appliances companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top tools and appliances companies are mixed at 10 a.m.:
WHR: 175.81 (+0.97), GE: 26.41 (+0.05)

Aerospace Suppliers Ramping Up To Meet Surging Orders, Says GE Capital
Business Wire - Fri Nov 07, 7:00AM CST
The aerospace supply industry is still in the early days of a long-term boom in orders, say industry participants at a recent suppliers summit hosted by GE Capital at GE Aviation's headquarters in Cincinnati, OH. The large majority of participants, who were split about evenly in serving wide-body and narrow-body commercial aircraft platforms said they plan to increase their workforce over the next 12 months (84%), expect to win new long-term supply agreements in the next three years (91%), and expect aircraft deliveries to continue to grow at least through 2016 (76%).
GE: 26.41 (+0.05)

GE Antares Capital Finances Kohlberg & Company's Acquisition of PPC Industries, Inc.
Business Wire - Fri Nov 07, 7:00AM CST
GE Antares, a unit of GE Capital, announced today it is serving as administrative agent on a $160 million senior secured credit facility to support the acquisition of PPC Industries, Inc. by Kohlberg & Company. GE Capital Markets served as lead arranger and bookrunner on this facility.
GE: 26.41 (+0.05)

Global Cell Expansion Market Outlook 2019 - Product, Cell Type, Application & End User Analysis of the $14 Billion Industry
M2 - Fri Nov 07, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/hw245b/cell_expansion) has announced the addition of the "Cell Expansion Market by Product , Cell Type, Application, End User - Forecast to 2019" report to their offering. The global cell expansion market is expected to reach $14.8 billion by 2019 from $6.0 billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019 The global cell expansion market is categorized on the basis of product, cell type, application, end user, and geography. The human cell expansion segment is expected to register the highest growth rate in the cell expansion market, by cell type, during the forecast period. Its favorable growth is attributed to increasing focus on human stem cell research and the increasing usage of stem cell for treating various disorders. Also, the market of regenerative medicines is expected to grow at highest CAGR in the cell expansion application market. This growth is attributed to the increasing government investments and technological advancements in this segment. Major factors contributing to growth of the cell expansion market include the increasing research activities, technological advancements, high prevalence of chronic diseases, and rising investments by companies are likely to propel the growth of this market. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in April 2013, the Scottish government granted $13.5 million to the College of Life Sciences at the University of Dundee (Scotland) for development of advanced stem cell technology. The relatively untapped markets of the Asian region and advent of 3D technology in cell expansion have opened an array of opportunities for the cell expansion market. However, the high cost of instruments and ethical concerns are expected to restrain the growth of this market. Scope of the Report Product - Reagent - Media - Serum - Bioreactors - Centrifuge Cell Type - Human - Animal Application - Stem Cell Research - Regenerative Medicine - Clinical Diagnostics End User - Hospital - Biotechnology - Cell Bank) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Cell Expansion Market, By Product 8 Cell Expansion Market, By Cell Type 9 Cell Expansion Market, By Application 10 Cell Expansion Market, By End User 11 Cell Expansion Market, By Geography 12 Competitive Landscape 13 Company Profiles - Beckman Coulter (Subsidiary of Danaher Corporation) - Becton Dickinson and Company - Corning Incorporated - Ge Healthcare (A Fully Owned Subsidiary of General Electric Company) - Merck Millipore (A Segment of Merck Kgaa) - Miltenyi Biotec - Sigma-Aldrich Corporation - Stemcell Technologies - Terumo BCT (A Subsidiary of Terumo Corporation) - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/hw..._expansion
GE: 26.41 (+0.05), SIAL: 135.34 (unch), MRK: 59.34 (+0.08), DHR: 81.19 (-0.07)

Southcross Holdings LP Announces $210 Million Capital Commitment from Energy Capital Partners and GE Energy Financial Services
Business Wire - Fri Nov 07, 6:00AM CST
Southcross Holdings LP ("Holdings" announced today the completion of a $210 million preferred equity commitment from Energy Capital Partners Mezzanine Opportunities Fund and GE Energy Financial Services. Holdings owns 100% of Southcross Energy Partners GP, LLC, the general partner of Southcross Energy Partners, L.P. (NYSE:SXE) ("Southcross" , limited partner interests in Southcross, and several Eagle Ford based midstream assets.
GE: 26.41 (+0.05), SXE: 19.04 (+0.57)

GE Oil & Gas to invest USD60m in Lufkin, Texas foundry
M2 - Fri Nov 07, 5:40AM CST
GE Oil & Gas, a business division of GE (NYSE: GE) focused on the oil and gas industry, announced on Thursday plans to invest USD60m in expanding and modernising its foundry operations in Lufkin, Texas.
GE: 26.41 (+0.05)

Global Oligonucleotide Synthesis Market Outlook, 2019 - Product & Services, End-User & Application Analysis of the $1.7 Billion Industry
M2 - Fri Nov 07, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/2c8kv2/oligonucleotide) has announced the addition of the "Oligonucleotide Synthesis Market by Product & Services, End-User , Application - Global Forecast to 2019" report to their offering. The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019 The global oligonucleotide synthesis market is categorized on the basis of products and services, applications, end users, and geography. The synthesized oligonucleotides segment is expected to register the highest growth rate in the oligonucleotide synthesis market during the forecast period, owing to an increasing number of applications for synthesized oligonucleotides in research, diagnostics and therapeutics; and a growing demand for custom oligos. Major factors contributing to growth of the oligonucleotide synthesis market include growing R&D expenditure in pharmaceutical and biotech companies; emerging applications of oligos in molecular diagnostics and synthetic biology; and evolving significance of RNA-interference oligos in therapeutics and diagnostics. Furthermore, government support and venture capital funding are other major factors that will boost the growth of this market. For instance, the U.S. National Institutes of Health (NIH) spend $1.5 billion per year to support their oligonucleotide-based applications. Further, in January 2013, Solstice Biologics, a South California start-up, raised $18 million in a series-A financing backed by venture capital funding for targeting and delivery of nucleic acid therapeutics. The relatively-untapped markets of the Asia-Pacific (APAC) region and the increasing R&D activities and funding there have opened up an array of opportunities for the oligonucleotide synthesis market. However, factors such as regulatory barriers, especially for therapeutic oligos, and downward pricing pressure may restrain the growth of this market. Scope of the Report Product & Services - Equipment - Reagent - Primer - Probe - Custom Oligos End-User - Research - Pharmaceutical & Biotechnology Application - Diagnostics - PCR - QPCR - Gene Synthesis - NGS - DNA - RNAi Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Oligonucleotide Synthesis Market By Products & Services 8 Global Oligonucleotide Synthesis Market, By Application 9 Global Oligonucleotide Synthesis Market, By End User 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - Bioautomation Corporation - Biosearch Technologies, Inc. - Eurofins Genomics (A Subsidiary of Eurofins Scientific Group) - Eurogentec (A Subsidiary of Kaneka Corporation) - GE Healthcare (A Subsidiary of General Electric Company) - Genedesign, Inc. - Integrated Dna Technologies - Sigma-Aldrich Corporation - Trilink Biotechnologies, Inc. - thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/2c...nucleotide
GE: 26.41 (+0.05), SIAL: 135.34 (unch)

General Electric's
at Investor's Business Daily - Thu Nov 06, 5:49PM CST
General Electric's (GE) oil and gas segment will invest $60 mil in improving its Lufkin, Texas-based foundry, which makes iron castings used in pumping units and power transmission equipment. The move comes amid GE's push to focus on its industrial...
GE: 26.41 (+0.05)

Skyworks Revenue Soars In Q4 As It Taps New Markets
at Investor's Business Daily - Thu Nov 06, 5:26PM CST
Skyworks Solutions late Thursday reported fiscal Q4 sales and earnings that handily beat Wall Street estimates, as did the company's outlook for the current quarter. Investors, however, apparently wanted more upside from the Apple (AAPL) supplier, as...
GPRO: 79.06 (+0.30), GE: 26.41 (+0.05), SWKS: 59.88 (-2.26), TQNT: 22.07 (-0.82), GM: 31.59 (+0.22), COL: 84.80 (+0.82), AAPL: 109.01 (+0.31), RFMD: 13.23 (-0.53)

Look for Shares of General Electric to Potentially Pullback after Yesterday's 2.09% Rise
Comtex SmarTrend(R) - Thu Nov 06, 3:39PM CST
General Electric (NYSE:GE) traded in a range yesterday that spanned from a low of $25.87 to a high of $26.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $25.90 on volume of 40.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GE: 26.41 (+0.05)

After Yesterday's Rally of 2.09% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 3:39PM CST
General Electric (NYSE:GE) traded in a range yesterday that spanned from a low of $25.87 to a high of $26.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $25.90 on volume of 40.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GE: 26.41 (+0.05)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 26

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading

Top 5 Most Recently Viewed Articles

NuCana Discontinues Phase 2 Colorectal Cancer Study

Updated Category News Views 146

NuCana Provides Update on Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study Discontinued Following Initial Analysis Ongoing Studies Show Promise with NUC-7738 and Pembrolizumab NuCana plc (NASDAQ: NCNA) has shared important updates about its clinical trials focused on innovative treatments for colorectal cancer. The company has made the decision to discontinue...

Continue Reading
Brøndbyernes IF Football Meeting - Key Highlights Recap

Updated Category News Views 179

Overview of the Annual General Meeting for Brøndbyernes IF Football A/S BRØNDBYERNES I.F. FODBOLD A/S CVR-nr. 83 93 34 10 This report summarizes the outcomes of the annual general meeting conducted by Brøndbyernes IF Football A/S. Key Date and Location The annual shareholders meeting took place, gathering stakeholders and shareholders at the club's headquarters. A...

Continue Reading
Uncovering the Wealth from Investing in BlackRock

Updated Category News Views 314

The Potential Growth of $1000 in BlackRock Investors often wonder how their money would grow over time if invested in strong companies. Recently, we looked into BlackRock, Inc., known by its stock ticker BLK. Over a span of 15 years, investing just $1000 into BlackRock stocks would yield an impressive value today. According to current evaluations, if you had made that...

Continue Reading
Zealand Pharma Advances Glepaglutide Approval for SBS Treatment

Updated Category News Views 267

Glepaglutide Submission to EMA Marks Significant Progress Zealand Pharma A/S, a pioneering biotechnology company, has recently shared exciting news about its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its innovative drug, glepaglutide. This long-acting GLP-2 analog is specifically designed for treating adults suffering from short...

Continue Reading
Seven Gables Real Estate Partners with Local Logic for Insights

Updated Category News Views 40

Seven Gables Real Estate Partners with Local Logic In a significant move that underscores their dedication to innovation, Seven Gables Real Estate has announced an exciting partnership with Local Logic, a leader in location intelligence. This collaboration is set to incorporate Local Logic's cutting-edge products—Local Content, Local Search, and NeighborhoodWrap—into...

Continue Reading